ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Immune Globulin Subcutaneous Human

Its studies are mostly in Agammaglobulinemia · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, led by Grifols.

Furthest: phase 3, since Dec 1, 20222 company-led studies, 2 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Grifols22 open or runningphase 3since Dec 1, 2022Dec 1, 2022Dec 31, 2027phase 3 · NCT07540221

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 1, 2022First study: phase 3 study in AgammaglobulinemiaFirst studyNCT05645107 · 386 planned · United States, Bosnia and Herzegovina, Bulgaria and more
  2. Apr 9, 2026Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT07540221 · 40 planned · United States, Czechia, Poland and more

Ahead

  1. Dec 31, 2027Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT07540221
  2. Aug 2029Primary completion: phase 3 study in AgammaglobulinemiaNCT05645107

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07540221Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Czechia, Poland and more3RecruitingDec 31, 202740
NCT05645107Agammaglobulinemia · United States, Bosnia and Herzegovina, Bulgaria and more3RecruitingAug 2029386

How it is read

Names in the registry

  • “Xembify”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Immune Globulin Subcutaneous Human (Grifols): development program | ClinicalTrials.gg